Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Rhea-AI Summary

Aquestive Therapeutics (NASDAQ: AQST) will report third quarter results for the period ended September 30, 2025 after market close on Wednesday, November 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, November 6, 2025. Investors must register in advance to obtain a local or toll-free number and personal pin. A live webcast will be available on the company’s Investors website and a replay will be archived for 30 days at https://investors.aquestive.com/events-and-presentations.

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025.

Management will host a conference call for investors at 8:00 a.m. ET on Thursday, November 6, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on the Investors section of Aquestive’s website at: Third Quarter 2025 Earnings Call

Following the call, a replay of the webcast will be available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.

About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Inquiries
Astr Partners
Brian Korb
Brian.korb@astrpartners.com

FAQ

When will Aquestive (AQST) report Q3 2025 results and hold the earnings call?

Aquestive will report Q3 results after market close on November 5, 2025 and hold a call at 8:00 a.m. ET on November 6, 2025.

How can investors join the Aquestive (AQST) November 6, 2025 conference call?

Investors must register in advance to obtain a local or toll-free phone number and a personal pin to join the call.

Where can I watch the live webcast of Aquestive (AQST) Q3 2025 earnings call?

The live webcast will be available on Aquestive’s Investors website and linked under Events and Presentations.

Will a replay of the Aquestive (AQST) Q3 2025 earnings webcast be available?

Yes. A replay of the webcast will be archived on the Investors site for 30 days at https://investors.aquestive.com/events-and-presentations.

What time zone is used for the Aquestive (AQST) November 6, 2025 earnings call?

The call time is given in Eastern Time (ET); the call starts at 8:00 a.m. ET on November 6, 2025.

What will Aquestive (AQST) cover in the November 5–6, 2025 announcement and call?

The company will report its third quarter ended September 30, 2025 financial results and provide an update on recent business developments.